Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.31 USD
-0.19 (-5.43%)
Updated Sep 6, 2024 03:39 PM ET
After-Market: $3.37 +0.06 (1.81%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CELZ 3.31 -0.19(-5.43%)
Will CELZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CELZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CELZ
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
CELZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Other News for CELZ
CELZ Stock Earnings: Creative Medical Tech Misses EPS for Q2 2024
Creative Medical starts development of AI-driven diagnostic, treatment program
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
Creative Medical Technology Holdings Provides Corporate Update
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz? Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin